Karyopharm - oncology

Quote












Clearly we received the NASDAQ warning letter. How in the world is no one taking a leadership position and discussing this with us??? Before you jump in I get it, we do not have any true leaders here, but the uncertainty and ambiguity this has created is not good for morale or productivity or retainment. Are they really that clueless? Do they really not understand the feeling many of us are having?

We are talking about people's livelihoods and there is crickets. Tells you all you need to know about our "executive leadership" team.
 




anonymous said:
Clearly we received the NASDAQ warning letter. How in the world is no one taking a leadership position and discussing this with us??? Before you jump in I get it, we do not have any true leaders here, but the uncertainty and ambiguity this has created is not good for morale or productivity or retainment. Are they really that clueless? Do they really not understand the feeling many of us are having?

We are talking about people's livelihoods and there is crickets. Tells you all you need to know about our "executive leadership" team.
Click to expand...

Hey, cut them some slack. Senior management has been really busy recently interviewing for other jobs.
 




























“XPOVIO net product revenue was adversely impacted year-over-year by increased utilization of the KaryForward Patient Assistance Program (PAP), due to multiple myeloma foundation closures1, contributing to ~10% of total demand in 2023 as compared to ~5% in 2022, leading to ~$6 million impact. Additionally, increased competition and higher gross-to-net, driven by increased 340B discounts and Medicaid rebates during the year, adversely impacted XPOVIO net product revenue.”
 




anonymous said:
“XPOVIO net product revenue was adversely impacted year-over-year by increased utilization of the KaryForward Patient Assistance Program (PAP), due to multiple myeloma foundation closures1, contributing to ~10% of total demand in 2023 as compared to ~5% in 2022, leading to ~$6 million impact. Additionally, increased competition and higher gross-to-net, driven by increased 340B discounts and Medicaid rebates during the year, adversely impacted XPOVIO net product revenue.”
Click to expand...

I’ll translate. Sales down another 5% YOY. Clovis 2.0.
 












Company of the incompetent and inept. Employees still here either because they are stupid or nobody will hire them. Delisting around the corner or reverse split. Either way one step closer to bankruptcy.
 








How in the world did they ever decide on this CEO ?? He has to be the worst, most incompetent CEO in the universe. What has he done ?? He has missed on everything, even basic things like opening trial cites. He couldn't hit the side of a barn. What a dope.
 




anonymous said:
How in the world did they ever decide on this CEO ?? He has to be the worst, most incompetent CEO in the universe. What has he done ?? He has missed on everything, even basic things like opening trial cites. He couldn't hit the side of a barn. What a dope.
Click to expand...

He brought a sociopathic HR staff with him! He hit his SG&A cost reduction goals by driving out highly compensates talent that actually knew what there were doing and were a threat to little Dickie's incompetence...
 








Top Bottom
Back
Quote